Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 10/20 | 0.48 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.48 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | LPL | P06858 | 1/20 | 0.40 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.40 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.39 |
| ▸ | EIF4EBP1 | Q13541 | 1/20 | 0.39 |
| ▸ | LDHA | P00338 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4355886 | 0.86 | CHRM4 (0.48) | FFAR4FFAR1CHRM4 | |
| SCHEMBL13622685 | 0.85 | FFAR4 (0.59) | FFAR4FFAR1CHRM4SMN1; SMN2KDM4E | |
| Trifluoroacetic Acid SCHEMBL4357612 | 0.84 | FFAR4 (0.59) | FFAR4FFAR1CHRM4EIF4EBP1 | |
| SCHEMBL5800096 | 0.78 | FFAR2 (0.54) | FFAR4FFAR1CHRM4SMN1; SMN2RXFP1 | |
| SCHEMBL2527850 | 0.78 | SMN1; SMN2 (0.46) | FFAR4FFAR1CHRM4SMN1; SMN2RXFP1 | |
| SCHEMBL1025467 | 0.78 | HRH4 (0.43) | FFAR4FFAR1SMN1; SMN2MAPTKDM4E | |
| SCHEMBL4359206 | 0.78 | DPP4 (0.43) | FFAR4FFAR1CHRM4KDM4E | |
| SCHEMBL1024488 | 0.76 | KDM4E (0.53) | FFAR4FFAR1CHRM4KDM4E | |
| SCHEMBL4364982 | 0.76 | CHRM4 (0.46) | FFAR4CHRM4TP53KDM4E | |
| SCHEMBL1026537 | 0.76 | GAA (0.41) | FFAR4FFAR1CHRM4KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8871753-B2 | Macrocyclic compounds and their use as kinase inhibitors | INCYTE CORPORATION (US) | 2014-10-28 | — | — | US | disclosed |
| US-20090286778-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286778-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | JAK2, JAK1, ALK | FFAR4 2075/4885FFAR1 1611/4885CHRM4 4834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.